-
Subject Areas on Research
-
A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B.
-
A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931.
-
A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer.
-
A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.
-
A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease.
-
A trial of outpatient chemotherapy for recurrent head and neck tumors.
-
A+AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma.
-
Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status.
-
Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.
-
Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636.
-
Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.
-
Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line.
-
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
-
Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study.
-
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
-
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
-
Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.
-
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
-
Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B.
-
Combination chemotherapy in histiocytosis X.
-
Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1).
-
Combined treatment approaches in regionally advanced bladder cancer.
-
DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma.
-
Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
-
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
-
Effect of vinblastine on neurohypophysial and adenohypophysial microtubules.
-
Effect of vinblastine on rat liver ultrastructure.
-
Effect of vinblastine on the fine structure of the rat adrenal cortex.
-
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
-
Guanosinetriphosphatase activity of tubulin associated with microtubule assembly.
-
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study.
-
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.
-
Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.
-
How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?
-
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer.
-
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
-
In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma.
-
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
-
Influence of cytoskeletal assembly on phosphatidylcholine synthesis in intact phagocytic cells.
-
Long-term follow-up of survival in Hodgkin's lymphoma.
-
Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
-
Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.
-
Microtubule disruption leads to cellular contraction in human trabecular meshwork cells.
-
Mobility and distribution of a cell surface glycoprotein and its interaction with other membrane components.
-
Negatively stained vinblastine aggregates.
-
Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.
-
Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
-
Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.
-
P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine).
-
POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group.
-
Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.
-
Pancreatoblastoma in a teenage patient.
-
Paraneoplastic limbic encephalopathy with testicular carcinoma. A reversible neurologic syndrome.
-
Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
-
Phase I study of Doxil and vinorelbine in metastatic breast cancer.
-
Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332.
-
Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.
-
Radiation techniques for the treatment of Hodgkin's disease with combined modality therapy or radiation alone.
-
Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.
-
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.
-
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
-
Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer.
-
Reaction phenotyping of vinblastine metabolism in dogs.
-
Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group.
-
Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer.
-
Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha.
-
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
-
Simultaneous quantification of vinblastine and desacetylvinblastine concentrations in canine plasma and urine samples using LC-APCI-MS/MS.
-
Systemic chemotherapy for urothelial cancer.
-
The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
-
The patient experience of ABVD treatment in Hodgkin lymphoma: a retrospective cohort study of patient-reported distress.
-
Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors.
-
Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy.
-
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
-
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
-
Treatment of high-stage bladder cancer: case for adjunctive chemotherapy.
-
Update: vinorelbine (navelbine) in non-small cell lung cancer.
-
Vinblastine-related pain in tumors.
-
Vinorelbine (Navelbine) in non-small cell lung cancer: future directions.
-
Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.
-
Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid.